- Q4 Sales increase 29% to $353 Million - Q4 Entered Orders increase 30% to $321 Million - Q4 GAAP EPS from Continuing Operations increases 14% to $1.73 - Q4 Adjusted EPS from Continuing Operations increases 30% to $2.32 - FY 2025 Sales increase 19% to $1.1 Billion - FY 2025 Entered Orders increase 57% to $1.6 Billion - FY 2025 GAAP EPS from Continuing Operations increases 13% to $4.49 - FY 2025 Adjusted EPS from Continuing Operations increases 26% to $6.03 -St. Louis, Nov. 20, 2025 (GLOBE NEWSWIRE) -- ESCO ...

PHILADELPHIA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) announced today the closing of its previously announced offering of $700.0 million aggregate principal amount of 5.625% senior notes due 2034 (the “Notes”) through a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to certain persons outside of the United States pursuant to Regulation S, each under the Securities Act of 1933, as amended (t ...

TRAVERSE CITY, Mich., Nov. 20, 2025 (GLOBE NEWSWIRE) -- MachTen, Inc. (OTC: MACT) today announced financial results for the third quarter ended September 30, 2025. “Michigan Broadband delivered another quarter of disciplined execution, expanding our fiber footprint while continuing to invest in our teams, systems and capabilities that support scalable growth,” said Dan Miller, Chief Executive Officer. “We remain committed to building the most reliable network in every community we serve, driving long-term v ...

LITTLE ROCK, Ark., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Dillard’s, Inc. (NYSE: DDS) (the “Company” or “Dillard’s”) announced that the Board of Directors declared a special dividend of $30.00 per share on the Class A and Class B Common Stock of the Company. The special dividend is payable January 5, 2026 to shareholders of record as of December 12, 2025. In a joint statement, Dillard’s Chief Executive Officer, William Dillard, II and President Alex Dillard shared, “Today, we are excited to announce our largest ...

ST. LOUIS, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for October 31, 2025, to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed. Ronald J. Kruszewski, Chairman and Chief Executive Officer, said, “Total client assets and fee-based client assets reached record highs, increasing 12% and 18% year-over-year, respectively, ...

ST. PETERSBURG, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”), the insurance holding company of American Coastal Insurance Company (“AmCoastal”), announced today that its executive management team will participate in several investor conferences in December. The Company’s leadership, including Bennet Bradford Martz, President and Chief Executive Officer, and Svetlana Castle, Chief Financial Officer, will pro ...

WAIKOLOA, Hawaii, Nov. 20, 2025 (GLOBE NEWSWIRE) -- California Water Service Group (NYSE: CWT) subsidiary Hawaii Water Service (Hawaii Water) has filed a request with the Hawaii Public Utilities Commission (PUC) to increase water and sewer rates in its Kapalua water and wastewater systems for the first time since acquiring the systems in 2021. The request seeks to increase revenues by $2.2 million to recover increases in purchased water costs, higher operating expenses, and the cost of completed capital inv ...

Core Points - Senmiao Technology Limited has completed a registered direct offering, selling 1,350,000 shares and pre-funded warrants for a total of approximately $2.8 million before expenses [1][3] - The company plans to issue additional warrants for up to 4,510,000 shares, pending stockholder approval, with an exercise price of $1.26 per share [2][4] - The financing aims to strengthen the company's financial foundation and support its growth strategy, focusing on diversifying revenue streams [3] Offering Details - The shares were sold at a purchase price of $1.26 each, with gross proceeds of about $2.8 million [1] - The offering is conducted under a "shelf" registration statement effective since September 29, 2023, with a prospectus supplement filed on November 14, 2025 [3] - The warrants will be offered under exemptions from registration requirements, and a registration statement for the resale of warrant shares will be filed within 30 days after stockholder approval [4] Company Overview - Senmiao Technology Limited is headquartered in Chengdu, Sichuan Province, and provides automobile transaction services, including sales, financing, and operating leases in China [6]

Core Insights - Crinetics Pharmaceuticals has initiated the pivotal Phase 3 CAREFNDR trial to evaluate the efficacy and safety of paltusotine for treating carcinoid syndrome associated with neuroendocrine tumors, building on positive Phase 2 results [1][2][3] Company Overview - Crinetics Pharmaceuticals is focused on developing transformative therapies for endocrine diseases and related tumors, with a core expertise in targeting G-protein coupled receptors [7][8] - The company’s lead product, paltusotine, is the first once-daily oral treatment approved for adults with acromegaly who have had an inadequate response to surgery [8] Clinical Trial Details - The CAREFNDR trial will enroll 141 adults with carcinoid syndrome, randomizing participants in a 2:1 ratio to receive either paltusotine 80 mg or a matching placebo [2] - The primary endpoint of the trial is to measure the change in flushing episodes per day from baseline to Week 12, with bowel movement frequency as a key secondary endpoint [2] - Following the 16-week randomized period, the trial includes a 104-week open-label extension to evaluate long-term efficacy and safety [2] Product Information - Paltusotine is a selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide currently in Phase 3 development for carcinoid syndrome, showing rapid and sustained reductions in symptoms during Phase 2 trials [5][6] - Approximately 20% of patients with neuroendocrine tumors experience carcinoid syndrome, characterized by symptoms such as diarrhea and flushing [6] Future Development - Crinetics is also exploring additional treatment options for neuroendocrine tumors through CRN09682, an investigational anti-tumor candidate that has received Investigational New Drug clearance [3]

Core Viewpoint - MDB Capital Holdings is making significant progress in scaling its public venture platform and aims to create a diversified portfolio of high-potential public venture opportunities [3]. Operational Highlights - The company anticipates closing two offerings shortly: a $16.8 million private placement for Paulex Bio, focused on diabetes therapeutics, and a $20 million IPO for Buda Juice, which offers UltraFresh™ cold-crafted juices [8]. - MDB Capital has expanded its pipeline of early-stage, disruptive companies that have the potential to lead in new categories [8]. - The firm is improving the efficiency of its public venture platform to better identify and prepare new category-leading companies with disruptive technologies [8]. - MDB welcomed TCA Venture Group and Keiretsu Forum MST angel group investors into its latest offerings, enhancing its investor community [8]. - The company has broadened relationships with Registered Investment Advisors (RIAs) to attract new investors seeking alternative investment strategies [8].